MicrosoftExpandedEvidence: Low40/100

Zuellig Pharma ensures continuous access to medicines with AI-driven digital platform

Zuellig Pharma, a leading pharmaceutical distribution company in Singapore, launched a 24/7 digital engagement platform and mobile app to ensure reliable, authentic access to prescription drugs and medical supplies. The solution addresses disruptions such as lockdowns and supply chain interruptions. Utilizing Azure cloud, Power Platform, Dynamics 365, and AI, the platform enables customers to place orders anytime, while authentication technology verifies drug provenance to prevent counterfeiting. The implementation enhances supply chain reliability and maintains patient access to critical medications. By leveraging Microsoft's technologies, Zuellig Pharma streamlined customer engagement, increased transparency, and improved distribution processes, ultimately fostering trust among patients and partners. The system demonstrates advanced AI-powered automation tailored for the pharmaceutical and healthcare industry.

Organization
Zuellig Pharma
Industry
Pharma
Location
Singapore
Published
August 2019
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
Customer
Zuellig Pharma
Provider
Microsoft
Maturity
Unknown
Linked source
Microsoft News APAC

No explicit deployment-stage evidence found.

Customer identity supportedSource describes one deploymentMaturity evidence evaluated

Primary read

Use case focus

Showing 3 of 3

  • 124/7 Digital Medicine Engagement Platform
  • 2AI-powered Supply Chain Authentication
  • 3Automated Pharmaceutical Order Fulfillment
  • Launched a digital engagement platform and mobile app for 24/7 medicine ordering
  • Implemented authenticity verification using embedded AI and cloud technologies
  • Leveraged Azure cloud infrastructure and AI for secure, scalable operations
  • Used Power Platform and Dynamics 365 to automate and streamline customer interactions
  • Supply chain reliability improved
  • Continuous patient access to critical medications during disruptions
  • Increased trust with embedded drug authentication
Sources & evidence1
Evidence: Low40/100Evidence strength
  • Customer explicitly identified
  • Independent source available
  • Technical implementation details available
ExpandedExpanded

The same organization appears in newer AI deployment evidence.

  • Same organization re-documented as recently as 2020.

Measures whether this deployment's public evidence persists — not whether the system is still in production.

Type: News ArticlePublished: Aug 24, 2019Publisher: Microsoft News APACEvidence: SecondaryConfidence: Low

AI-generated summary. Verify important details with the linked sources before relying on this case.

Explore related AI use cases

Was this useful?

Community

Comments

No published comments yet.